Development and Validation of an HPLC-UV Method for Quantitation of Linezolid: Application to Resistance Study Using in vitro PK/PD Model

References

• Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001;61(4):525–551. published correction appears in Drugs 2003;63(19);61(4):2126. doi:10.2165/00003495-200161040-0000811324682
   PubMed Web of Science ®Google Scholar
• Doern CD, Park JY, Gallegos M, et al. Investigation of linezolid resistance in staphylococci and enterococci. J Clin Microbiol. 2016;54(5):1289–1294. doi:10.1128/JCM.01929-1526935728
   PubMed Web of Science ®Google Scholar
• Chen H, Li L, Liu Y, et al. in vitro activity and post-antibiotic effects of linezolid in combination with fosfomycin against clinical isolates of Staphylococcus aureus. Infect Drug Resist. 2018;11:2107–2115. doi:10.2147/IDR.S17597830464553
   PubMed Web of Science ®Google Scholar
• Zhou YF, Xiong YQ, Tao MT, et al. Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to in vitro. J Antimicrob Chemother. 2018;73(7):1899–1907. doi:10.1093/jac/dky12929897466
   PubMed Web of Science ®Google Scholar
• Louie A, Maynard M, Duncanson B, et al. Determination of the dynamically linked indices of fosfomycin for Pseudomonas aeruginosa in the hollow fiber infection model. Antimicrob Agents Chemother. 2018;62(6):e02627–17. doi:10.1128/AAC.02627-1729581114
   PubMed Web of Science ®Google Scholar
• Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(4):iv7–iv15. doi:10.1093/jac/dkr07221521707
   PubMed Web of Science ®Google Scholar
• Boak LM, Li J, Nation RL, Rayner CR. High-performance liquid chromatographic method for simple and rapid determination of linezolid in human plasma. Biomed Chromatogr. 2006;20(8):782–786. doi:10.1002/bmc.59716292746
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Dixson S, et al. Simple method for the assay of linezolid in brain heart infusion broth by high-performance liquid chromatography. Biomed Chromatogr. 2004;18(1):1–5. doi:10.1002/bmc.28314872541
   PubMed Web of Science ®Google Scholar
• Toutain J, Boselli E, Djabarouti S, et al. Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813(1–2):145–150. doi:10.1016/j.jchromb.2004.09.030
   Web of Science ®Google Scholar
• Davis LT, Kumar N, Nijm LM, et al. An adaptable HPLC method for the analysis of frequently used antibiotics in ocular samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(26):2421–2426. doi:10.1016/j.jchromb.2010.08.001
   PubMed Web of Science ®Google Scholar
• Ba BB, Nso BB, Quentin C, et al. Determination of linezolid in growth media by high-performance liquid chromatography with on-line extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;854(1–2):104–108. doi:10.1016/j.jchromb.2007.04.011
   Web of Science ®Google Scholar
• CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 11th ed. CLSI standard M07. Wayne, PA: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• Stalker DJ, Jungbluth GL, Hopkins NK, et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother. 2003;51(5):1239–1246. doi:10.1093/jac/dkg18012668582
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42(13):1129–1140. doi:10.2165/00003088-200342130-0000414531724
   PubMed Web of Science ®Google Scholar
• Bioanalytical method validation guidance for industry. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed November 22, 2021.
   Google Scholar
• Lodise TP Jr, McKinnon PS. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy. 2007;27(7):1001–1012. doi:10.1592/phco.27.7.100117594206
   PubMed Web of Science ®Google Scholar
• Chavanet P. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Med Mal Infect. 2013;43(11–12):451–455. doi:10.1016/j.medmal.2013.09.01124238896
   PubMed Web of Science ®Google Scholar
• Fernandes GFDS, Salgado HRN, Santos JLD. A critical review of HPLC-based analytical methods for quantification of Linezolid. Crit Rev Anal Chem. 2020;50(3):196–211. doi:10.1080/10408347.2019.160587631017000
   PubMedGoogle Scholar
• Kumar L, Yadav YS, Rathnanand M. Simultaneous determination of linezolid and levamisole hydrochloride in a fixed dose combination. Indian J Pharm Educ Res. 2017;51(4):613–619. doi:10.5530/ijper.51.4.91
   Web of Science ®Google Scholar
• Allen GP, Cha R, Rybak MJ. In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2002;46(8):2606–2612. doi:10.1128/AAC.46.8.2606-2612.200212121940
   PubMed Web of Science ®Google Scholar
• Cha R, Akins RL, Rybak MJ. Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Pharmacotherapy. 2003;23(12):1531–1537. doi:10.1592/phco.23.15.1531.3196414695032
   PubMed Web of Science ®Google Scholar
• Gunderson BW, Ibrahim KH, Peloquin CA, et al. Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2003;47(1):398–399. doi:10.1128/AAC.47.1.398-399.200312499223
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Batard E, Perez L, et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother. 2002;46(12):3706–3711. doi:10.1128/AAC.46.12.3706-3711.200212435665
   PubMed Web of Science ®Google Scholar
• LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004;48(12):4665–4672. doi:10.1128/AAC.48.12.4665-4672.200415561842
   PubMed Web of Science ®Google Scholar
• Cha R, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2003;47(12):3960–3963. doi:10.1128/AAC.47.12.3960-3963.200314638509
   PubMed Web of Science ®Google Scholar
• Cha R, Rybak MJ. Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2003;47(6):1984–1987. doi:10.1128/AAC.47.6.1984-1987.200312760880
   PubMed Web of Science ®Google Scholar
• Oramas-Shirey MP, Buchanan LV, Dileto-Fang CL, et al. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother. 2001;47(3):349–352. doi:10.1093/jac/47.3.34911222569
   PubMed Web of Science ®Google Scholar
• Boak LM, Li J, Rayner CR, et al. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother. 2007;51(4):1287–1292. doi:10.1128/AAC.01194-0617242144
   PubMed Web of Science ®Google Scholar
• Firsov AA, Alieva KN, Strukova EN, et al. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model. J Antimicrob Chemother. 2017;72(11):3100–3107. doi:10.1093/jac/dkx24928981793
   PubMed Web of Science ®Google Scholar
• Firsov AA, Golikova MV, Strukova EN, et al. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of “antimutant” linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015;59(2):1014–1019. doi:10.1128/AAC.04214-1425451050
   PubMed Web of Science ®Google Scholar
• Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36(2):159–168. doi:10.1086/34574412522747
   PubMed Web of Science ®Google Scholar
• Pai MP, Rodvold KA, Schreckenberger PC, et al. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 2002;35(10):1269–1272. doi:10.1086/34417712410489
   PubMed Web of Science ®Google Scholar
• Roberts SM, Freeman AF, Harrington SM, et al. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J. 2006;25(6):562–564. doi:10.1097/01.inf.0000219401.70804.1a16732160
   PubMed Web of Science ®Google Scholar
• Firsov AA, Smirnova MV, Lubenko IY, et al. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother. 2006;58(6):1185–1192. doi:10.1093/jac/dkl38717028094
   PubMed Web of Science ®Google Scholar
• Wu D, Yan B, Yang X, et al. Whole-genome sequencing for detecting linezolid resistance in a patient with persistent methicillin-resistant Staphylococcus aureus infection during linezolid exposure. Int J Antimicrob Agents. 2020;55(1):105819. doi:10.1016/j.ijantimicag.2019.09.02331600555
   PubMed Web of Science ®Google Scholar
• Jiang L, Xie N, Chen M, et al. Synergistic combination of linezolid and fosfomycin closing each other’s mutant selection window to prevent enterococcal resistance. Front Microbiol. 2021;11:605962. doi:10.3389/fmicb.2020.60596233633692
   PubMed Web of Science ®Google Scholar